UPB – upstream bio, inc. (US:NASDAQ)

News

Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Upstream Bio (UPB) was downgraded by Wall Street Zen from "hold" to "s
Upstream Bio (UPB) was downgraded by Evercore Inc from "outperform" to "in-line". They now have a $15.00 price target on the stock.
Upstream Bio reports Q4 results [Seeking Alpha]
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com